Unappealing Biotech Products
It appears that the EC has decided not to appeal the panel ruling in Biotech. Why? And what are the jurisprudential and practical implications of this decision?
It appears that the EC has decided not to appeal the panel ruling in Biotech. Why? And what are the jurisprudential and practical implications of this decision?